NEW YORK (GenomeWeb News) – Vermillion said after the close of the market on Monday that it has sent Quest Diagnostics a notice of termination of their licensing deal covering the OVA1 and Vasclir diagnostic tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.